<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766816</url>
  </required_header>
  <id_info>
    <org_study_id>OPV-03/PR-15106</org_study_id>
    <secondary_id>PR-15106</secondary_id>
    <nct_id>NCT02766816</nct_id>
  </id_info>
  <brief_title>A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals</brief_title>
  <official_title>A Phase III, Observer Blind, Active Controlled, Randomized, Clinical Study Comparing Safety and Immunogenicity of BBio Bivalent Oral Polio Vaccine With a Licensed Bivalent Oral Polio Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bilthoven Biologicals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Serum Institute of India Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bilthoven Biologicals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bilthoven Biologicals has developed a new bivalent oral polio vaccine (bOPV) containing World
      Health Organization (WHO) approved Sabin strains of poliovirus type 1 and type 3. This study
      will assess non-inferiority of bOPV manufactured by BBio to that of licensed bOPV. This study
      will also assess lot-to-lot consistency among three lots of BBio bOPV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bilthoven Biologicals has developed a new bivalent OPV containing WHO approved Sabin strains
      of poliovirus type 1 and type 3. This phase III study will be conducted in two parts:

      Part 1 - 40 children of 60 to 83 months of age will be given single dose of BBio bOPV or
      licensed bOPV in 1:1 ratio. Primary objective is to assess safety of BBio bOPV.

      Part 2 - A total of 1080 infants of 42 to 56 days of age will be randomized to receive three
      doses of either BBio bOPV from one of the three lots or a licensed bOPV in 1:1:1:1 ratio as
      primary immunization series at 6, 10 and 14 weeks of age.

      Primary objective of this study is to assess non-inferiority of bOPV manufactured by BBio to
      that of licensed bOPV in terms of seroconversion. This study also will assess lot-to-lot
      consistency among three lots of BBio bOPV.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 8, 2016</start_date>
  <completion_date type="Anticipated">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">February 26, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 study: Frequency of adverse events (AEs)</measure>
    <time_frame>4 Days</time_frame>
    <description>Safety of single dose of BBio bOPV will be assessed at 4 days after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 study: Percentage of seroconversion to poliovirus type 1 and type 3</measure>
    <time_frame>one month after dose 3</time_frame>
    <description>Percentage of seroconversion to poliovirus type 1 and type 3 one month after administration of third dose of the BBio bOPV to that of control group bOPV to assess non-inferiority of BBio bOPV to that of a licensed bOPV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 study: Frequency of AEs and serious AEs (SAEs)</measure>
    <time_frame>28 days</time_frame>
    <description>Safety of single dose of BBio bOPV will be assessed at 28 days after vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 study: Percentage of seroprotection to poliovirus type 1 and type 3</measure>
    <time_frame>one month</time_frame>
    <description>Percentage of seroprotection to poliovirus type 1 and type 3 one month after administration of single dose of the BBio bOPV to that of control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 study: Geometric mean titers (GMTs) of poliovirus neutralizing antibody (PVNA) to poliovirus type 1 and type 3</measure>
    <time_frame>one month</time_frame>
    <description>GMTs of PVNA to poliovirus type 1 and type 3 at one month after administration of single dose of the BBio bOPV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 study: GMTs of serum PVNA for the three lots of BBio bOPV</measure>
    <time_frame>one month after dose 3</time_frame>
    <description>Serum PVNA concentrations expressed as GMTs for the BBio bOPV to assess equivalence in manufacturing consistency among three current Good Manufacturing Practices (cGMP) lots of the BBio bOPV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 study: GMTs of PVNA to poliovirus type 1 and type 3</measure>
    <time_frame>one month after dose 3</time_frame>
    <description>Comparison of GMTs of PVNA to poliovirus type 1 and type 3 at one month after administration of third dose of the BBio bOPV to that of control group bOPV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 study: Percentage of seroprotection to poliovirus type 1 and type 3</measure>
    <time_frame>one month after dose 3</time_frame>
    <description>Percentage of seroprotection to poliovirus type 1 and type 3 one month after administration of third dose of the BBio bOPV to that of control group bOPV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 study: Frequency of adverse events within 4 days following the administration of each dose of vaccine</measure>
    <time_frame>4 days after each dose of vaccine</time_frame>
    <description>Frequency of adverse events within 4 days following the administration of each dose of vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 study: Frequency of adverse events and serious adverse events</measure>
    <time_frame>84 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1120</enrollment>
  <condition>Immune Response to Oral Polio Vaccine</condition>
  <arm_group>
    <arm_group_label>Part 1 Study - BBio bOPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Study - Licensed bOPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Study - BBio bOPV Lot 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Study - BBio bOPV Lot 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Study - BBio bOPV Lot 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Study - Licensed bOPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Part 1 study - BBio bOPV</intervention_name>
    <description>A single dose of 2 drops (0.1 ml) orally of BBio bOPV to 20 children 60 to 83 months of age.</description>
    <arm_group_label>Part 1 Study - BBio bOPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Part 2 study - BBio bOPV Lot 1</intervention_name>
    <description>Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 1 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.</description>
    <arm_group_label>Part 2 Study - BBio bOPV Lot 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Part 2 study - BBio bOPV Lot 2</intervention_name>
    <description>Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 2 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.</description>
    <arm_group_label>Part 2 Study - BBio bOPV Lot 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Part 2 study - BBio bOPV Lot 3</intervention_name>
    <description>Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 3 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.</description>
    <arm_group_label>Part 2 Study - BBio bOPV Lot 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Part 2 study - Licensed bOPV</intervention_name>
    <description>Three doses of 2 drops (0.1 ml) orally of a licensed bOPV to 270 infants at 6-8, 10-12 and 14-16 weeks of age.</description>
    <arm_group_label>Part 2 Study - Licensed bOPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Part 1 study - Licensed bOPV</intervention_name>
    <description>A single dose of 2 drops (0.1 ml) orally of a licensed bOPV to 20 children 60 to 83 months of age.</description>
    <arm_group_label>Part 1 Study - Licensed bOPV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Normal healthy children of both sexes of age 5 to 6 years (60-83 months) at the time
             of vaccination and who have received at least 3 doses of trivalent oral polio vaccine
             (tOPV) based upon documentation (Study Part 1).

          2. Normal healthy infants of both sexes of age 6-8 weeks (42-56 days) at the time of the
             first vaccination and have not received oral polio vaccine (OPV) previously based upon
             documentation (Study Part 2).

          3. Parents/legal guardians of participants willing to give written informed consent and
             willing to comply with study protocol.

          4. Free of obvious health problems as established by medical history and screening
             evaluation including clinical examination.

          5. Resident of study area.

        Exclusion Criteria:

          1. Participation in another clinical trial in the 4 weeks preceding the (first) trial
             vaccination or planned participation in another clinical trial during the present
             trial period.

          2. A diagnosis or suspicion of congenital or acquired immunodeficiency disorder,
             malignancy, receiving immunosuppressive therapy such as systemic corticosteroids
             therapy for a period of â‰¥ 1 week either in the participant or in an immediate family
             member.

          3. A diagnosis or suspicion of bleeding disorder that would contraindicate collection of
             blood by venipuncture.

          4. Acute or persistent diarrhea (defined as diarrhea that lasts 14 days or longer),
             infection or illness at the time of enrollment (6-8 weeks of age) that would require
             participant's admission to a hospital or would contraindicate provision of OPV.

          5. Acute vomiting and intolerance to liquids within 24 hours before the enrollment visit.

          6. Infants from multiple births (i.e. twins).

          7. History of allergy or systemic hypersensitivity to any of the vaccine components or
             history of a life-threatening reaction to the study vaccines or a vaccine containing
             the same substances.

          8. Chronic illness at a stage that could interfere with trial conduct or completion.

          9. Planned administration/ administration of a vaccine not foreseen by the study protocol
             during the study period with the exception of routine Expanded Program on Immunization
             (EPI) program vaccines including pneumococcal vaccine, and rotavirus vaccine (Polio
             vaccines are not allowed during the study period).

         10. Blood or blood-derived products received in the past.

         11. Any vaccination one week preceding the trial vaccination.

         12. Presence of significant malnutrition (&lt; -3 standard deviation [SD] weight for length)
             or acute or chronic, clinically significant pulmonary, endocrine, autoimmune,
             cardiovascular, metabolic, hepatic or renal functional abnormality, as determined by
             medical history, and physical examination, which in the opinion of the investigator,
             might interfere with the study objectives

         13. History of any neurological disorder or history of seizure (febrile or afebrile), or
             encephalopathy, encephalitis, hypotonic-hyporesponsive episode.

         14. Febrile illness or acute illness on the day of inclusion is temporary exclusion
             criterion.

         15. Participant with any other condition, which, in the opinion of the investigator would
             jeopardize the safety or rights of the participant participating in the study or
             making it unlikely the participant, could complete the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>83 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K Zaman, MBBS, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Center for Diarrheal Disease Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Matlab Hospital Research Centre, International Center for Diarrheal Disease Research, Matlab</name>
      <address>
        <city>Matlab South, Chandpur District</city>
        <state>Chittagong Division</state>
        <zip>3640</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

